Perrigo buys OTC products from Aspen Global for $51m - 1 views
-
Alex Parker on 05 Mar 14Ireland-based Perrigo Company has acquired a basket of value-brand OTC products sold in Australia and New Zealand from Aspen Global for $51m.
Group items tagged
How a pharmaceutical market researcher is frustrated? - 0 views
-
Not that long ago, I was updating a key research project here at Best Practices; and as usual, I was waiting on approval from our research manager...
Prostate Cancer Diagnosis Has Not Deterred Larry Hagman From Working | MedIndia - 0 views
-
Brave heart Larry Hagman has vowed to keep on working despite battling prostate cancer.
Dementia Spending in Britain Tops £34 Billion a Year | MedIndia - 0 views
-
A new study has revealed that Britain spends over £34 billion a year on the care for patients suffering from Alzheimer's disease and dementia.
Liver Cancer Surgery: The Ultimate Guide to Treatment and Recovery - 0 views
-
Liver cancer surgery involves removing the cancerous tissue from the liver, and it can be done in several ways, depending on the stage of the cancer and the patient's overall health.
Prevention Cream For Stretch Marks - 1 views
I was really afraid to get pregnant because I knew then that my skin will be prone to stretch marks. That is why I have researched on How to get rid of stretch marks to prevent it from appearing o...
Child Therapy Works - 2 views
I have the chance of asking professional help for my kid who has been depressed for the past few weeks. We did not know what the reason was and so we asked help from NLP4Kids a reputed therapy orga...
OctreoPharm's OPS202 gets EMA orphan drug designation for management of GEP-NETs - 0 views
-
Germany-based OctreoPharm Sciences has received Orphan Drug Designation from the European Medicines Agency (EMA) for OPS202 as a diagnostic agent for the management of patients with gastro-entero-pancreatic-neuroendocrine tumors
BioLight announces start of clinical study with DiagnosTear dry eye syndrome diagnostic... - 0 views
-
BioLight Life Sciences Investments announced that DiagnosTear has received all necessary approvals from Sheba Medical Center near Tel Aviv to begin a clinical study with its TeaRx, point-of-care Dry Eye Syndrome diagnostic assay.
Otsuka- Lundbeck's schizophrenia drug Abilify Maintena gets Health Canada clearance - 0 views
-
Otsuka and Lundbeck has received approval from Health Canada to use its intramuscular (IM) once-monthly injectable formulation 'Abilify Maintena' for the maintenance treatment of schizophrenia in stabilized adult patients.
Bristol-Myers Squibb gets FDA breakthrough designation for daclatasvir-based regimen - 0 views
-
PBR Staff Writer Published 25 February 2014 Bristol-Myers Squibb (BMS) has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for its investigational DCV Dual Regimen (daclatasvir and asunaprevir) for use as a combination therapy in the treatment of genotype 1b chronic hepatitis C infection (HCV).
Vertex gets FDA approval for Kalydeco sNDA - 0 views
-
PBR Staff Writer Published 24 February 2014 US-based biotechnology firm Vertex Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for a supplemental New Drug Application (sNDA) of its Kalydeco (ivacaftor) for the treatment of people with cystic fibrosis (CF).
Edison's EPI-743 gets FDA fast track status to treat Friedreich's Ataxia - 1 views
-
US-based Edison Pharmaceuticals has received Fast Track designation from the US Food and Drug Administration (FDA) for its lead drug EPI-743 to treat patients with Friedreich's ataxia.
Oramed gets third Australia patent for oral Exenatide - 1 views
-
Israel-based clinical-stage pharmaceutical firm Oramed Pharmaceuticals has received its third patent in Australia for oral administration of exenatide from the Australian government's patent office 'IP Australia'.
Boehringer's Pradaxa gets FDA approval for DVT, PE treatment - 1 views
-
Germany-based pharmaceutical firm Boehringer Ingelheim has received approval from the US Food and Drug Administration (FDA) for Pradaxa (dabigatran etexilate) to treat venous thromboembolism (VTE), which includes both deep venous thrombosis (DVT) and pulmonary embolism (PE).
Dainippon's Latuda gets approval in Canada to treat bipolar depression - 1 views
-
Dainippon Sumitomo Pharma (DSP) has received approval from Health Canada for use of Latuda (lurasidone HCl) as monotherapy or as adjunctive therapy with lithium or valproate to treat depressive episodes associated with bipolar I disorder.
GlaxoSmithKline's Tanzeum gets FDA approval for type 2 diabetes treatment - 1 views
-
GSK has received approval from FDA for its Tanzeum subcutaneous injection to improve glycemic control, along with diet and exercise, in adult patients with type 2 diabetes.
DesignMedix gets $3m NIH grant to develop low-cost malaria drug - 1 views
-
US-based biotech startup DesignMedix has received a grant of $3m from the National Institutes of Health (NIH) to continue the development and manufacturing of a new anti-malarial drug.
Latest Health News Updates - 0 views
-
Leading and reliable source of health news updates round the clock every day with RSS feeds
Novartis launches Lucentis PFS in Germany - 1 views
-
PBR Staff Writer Published 21 March 2014 Novartis has launched the Lucentis (ranibizumab) pre-filled syringe (PFS) in Germany and plans to introduce the product in other markets throughout 2014. In October 2013, the company has received approval from the European authorities for Lucentis PFS, which is a new way of administering Lucentis that is specifically designed for intraocular injection to enhance patient safety and convenience for the treating clinician.
1 - 20 of 20
Showing 20▼ items per page